\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationOnline
Programmes1st EDF Online matchmaking event has now opened for registrations.
During this 1st matchmaking day the EOA* consortium offers the Defence and security industry the opportunity to meet and discuss opportunities in relation to the European Defence Fund.
The event will take place virtually on October 24th, 2024, from 1:00PM to 6:00PM. Registrations are now open until October 23rd, 2024, for participants to fill in their profiles. After having registered, you will be able to access to wide catalogue of potential partners and to send/receive meetings requests to be attended on that day.
The link to register and participate is the following: https://server.matchmaking-studio.com/en/EuropeenDefenceFundMatchmakingDay2024/
This matchmaking event enables EDF potential applicants to reach out to last-minute partners before the official EDF calls deadline of November 5th, 2024, and ask your questions to the Belgian NFP-team regarding several aspects such as the scope of your project, funding rates, eligibility of partners, costs, etc.
*Enhancing Opportunities for All (EOA) is a project funded by the European Defence Fund with two main target groups: enhancing skills network and tools for National Focal Points (NFPs) and supporting possible applicants for EDF projects to engage in consortia.
2 online matchmaking days per year will be organized.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
